| HOME >> BIOLOGY >> TECHNOLOGY |
development for the treatment of myelodysplastic syndrome (MDS).
Identification of a Novel Class of Nonpeptidyl Small-Molecule
Inhibitors of the Human Proteasome [Abstract # 3271]
The ubiquitin-proteasome system (UPS) mediated protein turnover underlies
many signaling pathways that are fundamental to cell proliferation,
survival and death. Many important cellular proteins that are
dysregulated in cancer are proteasome substrates. Telik researchers have
identified multiple nonpeptidyl small-molecule hits that inhibited human
proteasome activity both biochemically and in cells. The best series
exhibited many desirable features including excellent cellular specificity,
equal activity against all three proteolytic sites of the proteasome, and
potent and broad anti-tumor activity in vitro.
Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug
Discovery at Telik [Abstract # 4754]
Compounds for these preclinical studies came through the use of Telik's
TRAP technology, which provides an alternative screening method that is
based on a unique molecular descriptor called an affinity fingerprint. An
affinity fingerprint is based on the binding energy of small molecules to
proteins. Advanced computational methods are used to determine affinity
fingerprints, and to select compounds for screening. Advantages to using
TRAP include: a "low throughput" approach using complex, physiologically
relevant assays; identification of small molecule drug leads after testing
as few as 200 compounds; high level of success against a wide range of
cancer targets; enables scaffold hopping; and can speed the optimization
of small molecule drugs.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat serious d
'/>"/>
| SOURCE Telik, Inc. Copyright©2008 PR Newswire. All rights reserved |